Skip to search formSkip to main contentSkip to account menu

GSK249320

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Antibodies, Monoclonal, Humanized

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 8: A Phase IIb Double-blind, Randomized, Placebo Controlled Study of GSK249320 for Stroke Recovery
Introduction: One class of potential post-stroke restorative therapy focuses on promoting axon outgrowth by blocking myelin-based… 
2016
2016
GSK249320, A Monoclonal Antibody Against the Axon Outgrowth Inhibition Molecule Myelin-Associated Glycoprotein, Improves Outcome of Rodents with Experimental Stroke
Myelin-associated glycoprotein (MAG) is an inhibitor of axon growth. MAG levels increase after stroke. GSK249320 is a monoclonal… 
Review
2014
Review
2014
Methods for an International Randomized Clinical Trial to Investigate the Effect of Gsk249320 on Motor Cortex Neurophysiology using Transcranial Magnetic Stimulation in Survivors of Stroke
Introduction Transcranial Magnetic Stimulation (TMS) is a neurophysiological tool capable of assessing the motor nervous system… 
2013
2013
First‐Time‐in‐Human Study With GSK249320, a Myelin‐Associated Glycoprotein Inhibitor, in Healthy Volunteers
GSK249320, a monoclonal antibody directed against myelin‐associated glycoprotein (MAG), is being developed for the enhancement of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)